Abstract
Buspirone, an agonist of the 5-HT1A subtype of serotonin receptors, has shown antiemetic activity in animal models. However, in cancer patients treated with cisplatin, ondansetron, given either i.v. (one 8-mg dose 30 min after cisplatin) or orally (one 16-mg dose at the end of cisplatin infusion) was superior (P < 0.001) to buspirone (60 mg p.o. at the end of cisplatin and 60 mg p.o., 30 min later), in all parameters of antiemetic efficacy. These results are in favour of 5-HT3 receptors, but against the participation of 5-HT1A receptors in acute emesis associated with cisplatin chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alfieri, A., Cubeddu, L. Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients. Br J Cancer 72, 1013–1015 (1995). https://doi.org/10.1038/bjc.1995.452
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.452
This article is cited by
-
Référentiels inter régionaux en Soins Oncologiques de Support
Oncologie (2017)
-
The broad-spectrum antiemetic effects ETI-385 result from stimulation of 5-HT1A and 5-HT1D receptors
Experimental Brain Research (2014)
-
Intravenous buspirone for the prevention of postoperative nausea and vomiting
European Journal of Clinical Pharmacology (2012)
-
Serotonin pharmacology in the gastrointestinal tract: a review
Naunyn-Schmiedeberg's Archives of Pharmacology (2008)
-
The Partial 5-Hydroxytryptamine1A Receptor Agonist Buspirone does not Antagonize Morphine-induced Respiratory Depression in Humans
Clinical Pharmacology & Therapeutics (2007)